Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone240-268-2000
Debt
Current Ratio3.44
Quick Ratio3.44
Price-To-Earnings
Sales & Book Value
Annual Sales$31.18 million
Price / Sales26.03
Price / Cash FlowN/A
Price / Book-6.84
Profitability
Net Income$-183,760,000.00
Net Margins-482.87%
Return on Assets-66.83%
Miscellaneous
Employees347
OptionableOptionable
Novavax (NASDAQ:NVAX) Frequently Asked Questions
What is Novavax's stock symbol?
Novavax trades on the NASDAQ under the ticker symbol "NVAX."
How were Novavax's earnings last quarter?
Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The biopharmaceutical company earned $7.70 million during the quarter, compared to analyst estimates of $9.63 million. Novavax's quarterly revenue was down 8.3% on a year-over-year basis. During the same period last year, the firm earned ($0.15) EPS. View Novavax's Earnings History.
When is Novavax's next earnings date?
What price target have analysts set for NVAX?
10 brokers have issued 1 year price objectives for Novavax's stock. Their forecasts range from $2.00 to $10.00. On average, they expect Novavax's share price to reach $4.2778 in the next twelve months. This suggests a possible upside of 101.8% from the stock's current price. View Analyst Price Targets for Novavax.
What is the consensus analysts' recommendation for Novavax?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novavax.
Has Novavax been receiving favorable news coverage?
Media headlines about NVAX stock have trended negative recently, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novavax earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the next few days.
Are investors shorting Novavax?
Novavax saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 58,279,086 shares, an increase of 8.9% from the December 14th total of 53,500,990 shares. Based on an average trading volume of 10,877,017 shares, the short-interest ratio is currently 5.4 days. Currently, 15.4% of the shares of the stock are sold short. View Novavax's Current Options Chain.
Who are some of Novavax's key competitors?
Some companies that are related to Novavax include argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Regenxbio (RGNX), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Rubius Therapeutics (RUBY) and Orchard Therapeutics (ORTX).
Who are Novavax's key executives?
Novavax's management team includes the folowing people:
- Mr. Stanley Charles Erck, Pres, CEO & Director (Age 71)
- Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 59)
- Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 53)
- Dr. Gregory M. Glenn, Pres of R&D (Age 65)
- Mr. Sven Andréasson M.B.A., Sr. VP of Corp. Devel. (Age 67)
How do I buy shares of Novavax?
Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novavax's stock price today?
One share of NVAX stock can currently be purchased for approximately $2.12.
How big of a company is Novavax?
Novavax has a market capitalization of $842.27 million and generates $31.18 million in revenue each year. The biopharmaceutical company earns $-183,760,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Novavax employs 347 workers across the globe.
What is Novavax's official website?
How can I contact Novavax?
Novavax's mailing address is 20 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]
MarketBeat Community Rating for Novavax (NASDAQ NVAX)
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
